Understanding Polycystic Ovary Syndrome Beyond the Diagnosis
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women, affecting an estimated 6–12% of the female population. Yet it remains consistently mismanaged in conventional medicine — often reduced to a fertility concern or treated with birth control as the sole intervention. Practitioners with a comprehensive understanding of PCOS pathophysiology deliver dramatically better long-term outcomes.
The Three PCOS Phenotypes
PCOS is not a single entity. It exists on a spectrum, with different hormonal drivers and metabolic profiles. The Rotterdam criteria require two of three features: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries on ultrasound. But the phenotype matters clinically — an insulin-resistant PCOS patient requires a different intervention than a lean PCOS patient with elevated LH.
The Insulin-Testosterone Connection
In the most common PCOS phenotype, hyperinsulinemia is the primary driver. Elevated insulin stimulates ovarian theca cells to overproduce androgens (testosterone, DHEA-S), while simultaneously suppressing SHBG — amplifying androgenic effects. This is why insulin sensitization (metformin, inositol, dietary intervention) often normalizes cycles and reduces androgen levels without any direct hormonal intervention.
Diagnostic Workup
Comprehensive PCOS evaluation includes: LH, FSH, LH:FSH ratio (typically >2:1 in PCOS), total and free testosterone, DHEA-S, SHBG, androstenedione, fasting glucose and insulin (HOMA-IR), prolactin (to rule out hyperprolactinemia), 17-OH progesterone (to rule out NCAH), TSH, and pelvic ultrasound. Not all are needed in every case, but the clinical picture guides selection.
First-Line Treatment: Lifestyle and Metabolic Optimization
Even modest weight loss (5–10% of body weight in overweight patients) significantly improves insulin sensitivity, lowers androgens, restores ovulation, and reduces long-term metabolic risk. A lower-glycemic diet, resistance training, and adequate sleep are foundational. Inositol (myo-inositol 4g + D-chiro-inositol 400mg daily) has strong evidence for improving insulin sensitivity, reducing androgens, and restoring ovulation specifically in PCOS.
Pharmacological Approaches
Metformin remains a cornerstone pharmacological tool in metabolic PCOS. For anovulation, clomiphene and letrozole (preferred for ovulation induction) are first-line. GLP-1 agonists show promise in overweight PCOS patients. Spironolactone is effective for hyperandrogenism symptoms (acne, hirsutism) and should be paired with contraception. Avoid long-term oral contraceptives as the primary management — they mask the condition without addressing root causes.